Patient-Focused Drug Development Meeting (Virtual)
Tuesday, June 9, 2020, from 12:30-4:30 p.m. EDT
The primary goal of this virtual (online) meeting is to hear directly from patients about their perspectives on living with chronic hepatitis B and their experiences with treatments, to improve the development of new drugs in the research pipeline. The patient perspective is critical in helping the U.S. Food and Drug Administration (FDA) understand the context in which regulatory decisions are made for new drugs. This input will inform FDA’s decisions and oversight both during drug development and during its review of new treatments.
The meeting format will be very interactive and include information on current and future hepatitis B treatments, hear direct voices from patients on their perspectives living with the disease and hopes for clinical trials and treatments, and a live Q&A with the audience. Audience participants will have a chance to comment during the meeting via phone and email! You can see the full meeting agenda here.
This is a unique chance for all those impacted by hepatitis B to share their voice - please join us!
If you’ve ever wanted to help guide the future of hepatitis B treatments, now is your chance! Please respond to one or more of the following questions in the "Email a Live Comment" section below the discussion questions:
